On May 25, Novavax, Inc. NVAX announced that it has started the phase 1 clinical trial of its coronavirus vaccine candidate, with preliminary results slated to come out in another couple of months.If successful, Novavax plans to go ahead with the phase 2 trial to assess immunity, safety and COVID-19 disease reduction in a broader age range in several countries, including the United States.